Developmental funds are requested to recruit faculty level scientists in areas of strategic need, to support pilot projects that allow Fox Chase Cancer Center scientists to pursue innovative ideas in high priority research areas, and to support technology and methodology development projects related to the Center's discovery mission and strategic objectives. In the past CCSG cycle, 40 investigators were recruited and, with the exclusion of our 17 newest recruits, 19 of 23 (83%) have obtained $15.4 million in peer reviewed funding within 24 months of their appointment Of that amount $5.1 million was garnered by investigators directly leveraging developmental funds. Also, this class competed successfully for a further $1.6 million in competitive foundation support. During the last CCSG cycle, pilot project funds were utilized in the second, fifth and sixth years to support potential high-impact projects, largely from established investigators. The 12 funded projects have already produced two funded grants and seven publications. During the past CCSG cycle, the Center provided start up support for a High Throughput Screening Facility that has become one of the 16 established shared facilities. In the present CCSG application we seek partial support for the 25 new investigators identified as necessary to address the critical mass needs of the Center's five existing programs over the next CCSG cycle. This request represents less than 25% of the average cost of supporting a new investigator. We also seek support for partial funding for four translational pilot projects per year. These CCSG funds will be matched by institutional funds. Finally, we seek partial funding for technology developments and informatics initiatives in support of the Center's Institute for Personalized Medicine. All of these developmental funds are considered vital to achieving the discovery objectives outlined in the Center's Strategic Plan.

Public Health Relevance

Development funds are critical for use in recruiting faculty level scientists and to support pilot projects at Fox Chase Cancer Center allowing scientists to pursue innovative ideas in high priority research areas. These funds are also necessary to promote emerging technologies used in cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006927-48
Application #
8335532
Study Section
Subcommittee G - Education (NCI)
Project Start
2011-07-21
Project End
2014-06-30
Budget Start
2011-07-21
Budget End
2012-06-30
Support Year
48
Fiscal Year
2011
Total Cost
$345,434
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Mortazavi, S M J; Bevelacqua, J J; Fornalski, K W et al. (2018) Comments on ""Space: The Final Frontier-Research Relevant to Mars"". Health Phys 114:344-345
Esposito, Andrew C; Crawford, James; Sigurdson, Elin R et al. (2018) Omission of radiotherapy after breast conservation surgery in the postneoadjuvant setting. J Surg Res 221:49-57
Dong, Yanqun; Zaorsky, Nicholas G; Li, Tianyu et al. (2018) Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. J Med Imaging Radiat Oncol 62:116-121
Ge, Yunhui; Borne, Elias; Stewart, Shannon et al. (2018) Simulations of the regulatory ACT domain of human phenylalanine hydroxylase (PAH) unveil its mechanism of phenylalanine binding. J Biol Chem 293:19532-19543
Chow, H Y; Dong, B; Valencia, C A et al. (2018) Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nat Commun 9:3473
Egleston, Brian L; Pedraza, Omar; Wong, Yu-Ning et al. (2018) Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible. Contemp Clin Trials Commun 9:135-142
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Reese, Jennifer Barsky; Sorice, Kristen; Lepore, Stephen J et al. (2018) Patient-clinician communication about sexual health in breast cancer: A mixed-methods analysis of clinic dialogue. Patient Educ Couns :
Wagner, Jessica; Kline, C Leah; Zhou, Lanlan et al. (2018) Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest 128:2325-2338
Araiza-Olivera, D; Feng, Y; Semenova, G et al. (2018) Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors. Oncogene 37:944-952

Showing the most recent 10 out of 1280 publications